Nabi Biopharmaceuticals Announces Second Quarter 2007 Financi...(of marketable securities (28500) ...),Health

Proceeds from sales of marketable

securities 25,575 29,550

Proceeds from sale of assets,

net of closing costs 1,300 8

Capital expenditures (568) (1,059)

Net cash used in investing activities

from continuing operations (2,193) (34,976)

Net cash provided by investing

activities from discontinued

operations 2,582 -

Net cash provided by (used in) investing

activities 389 (34,976)

Cash flow from financing activities:

Repayments of notes payable and

capital leases (137) (72)

Proceeds from exercise of employee

stock options 604 1,137

Net cash provided by financing activities

from continuing operations 467 1,065

Net cash provided by (used in) financing

activities from discontinued operations 292 (3,059)

Net cash provided by (used in) financing

activities 759 (1,994)

Net decrease in cash and cash equivalents (17,710) (70,641)

Cash and cash equivalents at beginning

of period 86,227 101,762

Cash and cash equivalents at end

of period $ 68,517 $ 31,121

Nabi Biopharmaceuticals

SUPPLEMENTAL SEGMENT INFORMATION

(Unaudited, in thousands)

Fo
'/>"/>

SOURCE Nabi Biopharmaceuticals Copyright©2007 PR Newswire.

0 GOOD